Axcelis Technologies, Inc. (Nasdaq: ACLS) — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request identifies 2022 Q4, this is an annual filing; it includes select fourth-quarter data, but not a complete quarterly income statement or cash-flow summary.
Business context
Axcelis designs, manufactures and services ion implantation equipment used in semiconductor manufacturing. Ion implantation represented 97.6% of 2022 revenue; the balance came from legacy processing systems and related aftermarket activity. The company cited demand for mature-process devices and power semiconductors, including devices used in vehicle electrification, as important growth drivers.
Financial performance
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $920.0 million | $662.4 million |
| Systems revenue | $692.1 million | $454.6 million |
| Aftermarket revenue | $227.9 million | $207.8 million |
| Gross profit / margin | $401.8 million / 43.7% | $286.4 million / 43.2% |
| Income from operations | $212.4 million | $127.3 million |
| Net income | $183.1 million | $98.7 million |
| Diluted earnings per share | $5.46 | $2.88 |
| Cash provided by operating activities | $215.6 million | $150.2 million |
Revenue increased 38.9%; systems revenue rose about 52%, while aftermarket revenue grew about 10%. Gross margin improved 0.5 percentage point. Operating expenses rose 19.0% to $189.4 million, but declined as a share of revenue to 20.5% from 24.0%. The 2022 effective tax rate was 10.6%, versus 18.1%, mainly reflecting a $20.5 million benefit related to foreign-derived intangible income (FDII).
Cash and liquidity: Cash and cash equivalents were $185.6 million at year-end, down from $294.9 million; short-term investments were $246.6 million. Working capital was $629.5 million. The company reported no bank borrowings. Its financing lease obligation was $46.4 million, and total lease liabilities were $58.7 million. Investing cash outflow was $257.3 million, largely reflecting purchases of short-term investments; capital expenditures were $10.7 million. Financing cash outflow was $65.5 million, including $57.5 million of share repurchases.
Inventory increased to $242.4 million from $195.0 million, and accounts receivable rose to $169.8 million from $104.4 million. Deferred revenue increased to $154.8 million from $68.4 million. Systems backlog, including deferred systems revenue, was $1.124 billion at year-end, compared with $460.6 million a year earlier; Q4 bookings were $211.5 million versus $194.0 million in Q4 2021. Backlog orders may be cancelled or rescheduled.
Material changes and management outlook
- Management described 2022 as a record year for revenue, gross margin and operating profit relative to the company’s public-company history. Growth was driven principally by Purion systems sales and a strong semiconductor equipment market.
- Mature-process devices accounted for more than 80% of systems shipments; power devices represented approximately 39% of shipments.
- Management’s 2023 strategic goal was to exceed $1.0 billion in revenue, with a longer-term $1.3 billion ion-implant revenue model. These are strategic objectives, not a detailed earnings forecast in the supplied filing text.
- The company plans approximately $19.1 million of 2023 capital expenditures and has committed to purchase orders totaling $412.3 million, approximately $403.9 million expected in 2023.
- Expansion plans included a 98,000-square-foot Beverly logistics and flex manufacturing center, with lease commencement expected in 2023.
Risks, contingencies and unusual items
- Semiconductor cycle and customer spending: Equipment demand depends on customer capital spending and is cyclical; fixed costs may amplify the effect of a downturn.
- Export controls and geographic exposure: 84.4% of revenue was international, and Asia represented a substantial share of system revenue. U.S. restrictions on shipments to certain Chinese customers could limit sales or prompt customers to switch to non-U.S. suppliers.
- Customer concentration: The top ten customers accounted for 59.4% of revenue. Two customers represented 13.1% and 11.5%, respectively; the filing identifies Samsung and SMIC among customers exceeding 10% of revenue.
- Supply chain and execution: Reliance on limited suppliers, long component lead times, logistics constraints and inventory forecasting could affect costs, deliveries and margins.
- Other exposures: Risks include competition, product development and acceptance, cybersecurity, foreign exchange, environmental and safety compliance, and potential pandemic-related disruption. No litigation was identified as likely to have a material adverse effect.
- Tax and lease matters: The filing reports $10.4 million of unrecognized tax benefits and $8.4 million of valuation allowance against certain tax assets. The $40 million revolving credit facility was undrawn at year-end, subject to a $5.9 million letter of credit, and was scheduled to terminate July 31, 2023.
Ernst & Young issued an unqualified opinion on the financial statements and concluded that internal control over financial reporting was effective.
Key facts for investors to verify
- Reconcile the filing’s overview statement that “operating profit” was $401.8 million with the audited statements: $401.8 million is gross profit, while audited income from operations was $212.4 million.
- Assess whether the 2023 $1.0 billion revenue objective is achievable amid semiconductor-cycle changes, export restrictions and customer spending uncertainty.
- Review backlog quality, cancellation and rescheduling rights, and the timing of recognition for the sharply higher deferred revenue balance.
- Monitor inventory, receivables and purchase commitments relative to shipment growth and future demand.
- Confirm the status of the revolving credit facility following its stated July 2023 termination date, and track lease obligations and the new manufacturing-center commitment.
- Evaluate customer and China exposure, including licenses and restrictions affecting shipments to SMIC and other customers.